UnknownPhase 4NCT05828147

Anti-CD20 Antibodies for Treatment of SLE-PAH

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chinese SLE Treatment And Research Group
Principal Investigator
Mengtao Li, Prof
Peking Union Medical College Hospital
Intervention
Rituximab(drug)
Enrollment
50 enrolled
Eligibility
18-65 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05828147 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus

← Back to all trials